MTOR and osteosarcoma: When looking ar osteosarcoma trials on the https://clinicaltrials.gov website, fewer than 15 currently opened protocols are using such strategies with HIFs inhibitors such as irinotecan, mTor inhibitors (ridaforolimus, everolimus, sirolimus) or AKT/Pi3K inhibition with dual mTOR/PI3K targeting.